%0 Journal Article %1 Zhou:2017:Cancer-Chemother-Pharmacol:28791452 %A Zhou, Z %A Howard, T A %A Villano, J L %D 2017 %J Cancer Chemother Pharmacol %K PAYWALL SHOULDREAD cancer-research long-term temozolomide %R 10.1007/s00280-017-3415-5 %T Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma %U https://www.ncbi.nlm.nih.gov/pubmed/28791452 %X Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense. Continuous daily dosing is available, but the acceptable dose and duration of therapy is unknown. We document a 40-year-old male with recurrent anaplastic astrocytoma, IDH mutant and MGMT promotor methylation negative, who has well-tolerated continuous daily TMZ for 20�months at 100�mg per day for nearly the length of this period. A trial at 80�mg per day demonstrated disease progression with response upon return to 100�mg per day. Prior to the daily TMZ, the patient underwent three surgical resections, radiation therapy with concurrent TMZ according to the EORTC-NCIC protocol, and subsequently bevacizumab in combination with use of the Optune device. Long-term survival of patients with recurrent malignant gliomas is uncommon, and currently no standard treatment strategies exist for these patients. We present this case to demonstrate the tolerability and dose dependency of prolonged daily TMZ dosing as a therapeutic option for recurrent anaplastic astrocytomas.

@article{Zhou:2017:Cancer-Chemother-Pharmacol:28791452, abstract = {Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense. Continuous daily dosing is available, but the acceptable dose and duration of therapy is unknown. We document a 40-year-old male with recurrent anaplastic astrocytoma, IDH mutant and MGMT promotor methylation negative, who has well-tolerated continuous daily TMZ for 20�months at 100�mg per day for nearly the length of this period. A trial at 80�mg per day demonstrated disease progression with response upon return to 100�mg per day. Prior to the daily TMZ, the patient underwent three surgical resections, radiation therapy with concurrent TMZ according to the EORTC-NCIC protocol, and subsequently bevacizumab in combination with use of the Optune device. Long-term survival of patients with recurrent malignant gliomas is uncommon, and currently no standard treatment strategies exist for these patients. We present this case to demonstrate the tolerability and dose dependency of prolonged daily TMZ dosing as a therapeutic option for recurrent anaplastic astrocytomas.}, added-at = {2017-09-10T22:59:25.000+0200}, author = {Zhou, Z and Howard, T A and Villano, J L}, biburl = {https://www.bibsonomy.org/bibtex/2d27aef6d7c290212dd16ed7222330e74/marcsaric}, description = {Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. - PubMed - NCBI}, doi = {10.1007/s00280-017-3415-5}, interhash = {b6ab75a21ceeee0e76e9e64a28fe1401}, intrahash = {d27aef6d7c290212dd16ed7222330e74}, journal = {Cancer Chemother Pharmacol}, keywords = {PAYWALL SHOULDREAD cancer-research long-term temozolomide}, month = aug, pmid = {28791452}, timestamp = {2017-09-10T22:59:49.000+0200}, title = {Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma}, url = {https://www.ncbi.nlm.nih.gov/pubmed/28791452}, year = 2017 }